" class="no-js "lang="en-US"> Susanne Schaffert - Medtech Alert
Monday, September 08, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Susanne Schaffert

Susanne Schaffert

About Susanne Schaffert

Susanne Schaffert, PhD, is president of Novartis Oncology, one of the first companies to form a global business unit dedicated to developing and launching innovative oncology medicines that address the unmet medical needs of people with cancer and related diseases. Susanne oversees more than 10,000 associates in 85 countries working to transform cancer care and address some of society’s most challenging health care issues through science-based innovation.

Related Story

Diseases

 Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive

Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer

March 24 2022

Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu […]

Diseases

 NHS Announces Deal for Life Changing Sickle Cell Treatment | Pharmtech Focus

NHS Announces Deal for Life Changing Sickle Cell Treatment

October 5 2021

The first treatment for sickle cell disease in over 20 years will be rolled out […]